GlaxoSmithKline (GSK) reported data showing that its H5N1 pandemic flu vaccine achieved a high immune response at a low dose of antigen. The vaccine enabled over 80% of subjects who received 3.8 micrograms of antigen to demonstrate a strong seroprotective immune response.

The results, GSK said, were based on an interim analysis of a clinical trial conducted in Belgium that involved 400 healthy adults aged 18-60 years. The vaccine tested was produced from inactivated H5N1 virus and contained a novel adjuvant. Trial participants were vaccinated twice and four different levels of antigen dose were tested, with 3.8 microgram being the lowest.

GSK’s adjuvanted investigational pandemic vaccine has not received marketing approval from any regulatory agency, noted company officials.

Previous articleGenomic Code for the Packaging of DNA within Nucleosomes Discovered
Next articleDr. Hui Lu and Ann Reed